1. Sudden Cardiac Arrest Foundation 2017. Available from http://www.sca-aware.org/about-sca.
2. Heart Rhythm Foundation 2017. Available from http://www.heartrhythmfoundation.org/facts/scd.asp.
3. Бокерия ЛА, Ревишвили АШ, Неминущий НМ. Внезапная сердечная смерть. М.: ГЭОТАР-Медиа, 2011; 267 с.
4. Bayes de Luna A, Coumel P, Leclerq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. American Heart Journal. 1989;117: 151-159. https://doi.org/10.1016/0002-8703(89)90670-4.
5. Albert CM, Chae CU, Grodstein F, et al. Prospective study of sudden cardiac death among women in the United States. Circulation. 2003;107: 2096-2101.
6. Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Circulation. 2006;113(6): 776-82. https://doi.org/10.1161/CIRCULATIONAHA.105.561571.
7. Ревишвили АШ, Бойцов СА, Давтян КВ, и др. Клинические рекомендации по применению кардиовертеров-дефибрилляторов. В кн. Клинические рекомендации 2017, 2017: 55-59.
8. Богачевская СА, Богачевский АН. Развитие хирургической и интервенционной аритмологии в России за 10 лет. Особенности функциоирования службы в дальневосточном регионе. Электронный научный журнал Социальные аспекты здоровья населения. 2017;1(53): 1-11.
9. Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverterdefibrilators in children and adults: cause for caution. Eur Heart J. 2012;33: 1351-1359.
10. Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. NEJM. 2010;363: 36-44.
11. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128(9): 944-53. https://doi.org/10.1161/CIRCULATIONAHA.113.003042.
12. Louise RA, Nordkamp MD, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: A Prospective, Randomized comparison of subcutaneous and transvenous Implantable cardioverter-defibrillator therapy. Am Heart J. 2012;163(5): 753-760.e2. https://doi.org/10.1016/j.ahj.2012.02.012.
13. Quast ABE, Baalman SWE, Betts TR, et al. Rationale and design of the PRAETORIAN-DFT trial: A prospective randomized CompArative trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation with and without DeFibrillation testing. Am Heart J. 2019;214: 167-174. https://doi.org/10.1016/j.ahj.2019.05.002.
14. Lambiase PD, Barr C, Theuns DAMJ, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J. 2014;35(25): 1657-65. https://doi.org/10.1093/eurheartj/ehu112.
15. Gold MR, Lambiase PD, El-Chami MF, et al. Primary results from the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low Ejection Fraction (UNTOUCHED) trial. Circulation. 2021;143: 7-17.
16. Gold MR, Aasbo JD, El-Chami MF, et al. Sub-cutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14(10): 1456-63.
17. Burke MC, Gold MR, Knight BP, et al.. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coil Cardiol. 2015;65: 1605-1615.
18. Kobe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm. 2013;18: 29-36.
